Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: Preliminary results

American Journal of Roentgenology

Volumn 196, Issue 6, 2011, Pages

  Horger, Marius ^a   Weisel, Katja ^a   Horger, Wilhelm ^b   Mroue, Ali ^a   Fenchel, Michael ^a   Lichy, Matthias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SIEMENS AG   (Germany)

Author keywords

Bortezomib; Cancer; Lenalidomide; Multiple myeloma; Therapy response monitoring; Whole body diffusion weighted MRI

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; ECHO PLANAR IMAGING; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; WHOLE BODY MRI;

AGED; ANTINEOPLASTIC AGENTS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 79960485182     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.5979     Document Type: Article

References (20)

1. Mazumdar A, Siegel MJ, Narra V, Luchtman-Jones L. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. AJR 2002; 179:1261-1266 (Pubitemid 35204384)
2. Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007; 26:498-509 (Pubitemid 350194569)
3. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010; 20:2027-2038
4. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11:102-125
5. Lichy MP, Aschoff P, Plathow C, et al. Tumor detection by diffusion-weighted MRI and ADCmapping: initial clinical experiences in comparison to PET-CT. Invest Radiol 2007; 42:605-613 (Pubitemid 47262928)
6. Li S, Xue HD, Li J, et al. Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma. Chin Med Sci J 2008; 23:138-144
7. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006; 6:135-143
8. Durie BG, Salmon SE. A clinical staging for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-854
9. Ludwig H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15:6-25
10. Richardson PG, Sonneveld P, Schuster MW, et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498
11. Sirohi B, Powles R. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2009; 9:1559-1570
12. Horger M, Kanz L, Denecke B, et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-1626 (Pubitemid 46595698)
13. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25:1121-1128 (Pubitemid 46596765)
14. Lin C, Luciani A, Belhadj K, et al. Multiple myeloma treatment response assessment with wholebody dynamic contrast-enhanced MR imaging. Radiology 2010; 254:521-531
15. Horger M, Fenchel M, Nägele T, et al. Water diffusivity: comparison of primary CNS lymphoma and astrocytic tumor infiltrating the corpus callosum. AJR 2009; 193:1384-1387
16. Woodhams R, Kakita S, Hata H, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging - comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 2010; 254:357-366
17. Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010; 254:170-178
18. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110:3557-3560 (Pubitemid 350159621)
19. Richardson, PG., Sonneveld, P, Schuster, MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498 (Pubitemid 41007864)
20. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116:3807-3814